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The glycoproteins recognized by m onoclonal antibody 
(mAb) NKI-beteb are among the best diagnostic markers 
for hum an melanoma because their expression is re­
stricted to m elanocytic cells. Recently, we isolated  a 
cDNA clone, term ed gplOO-cl, which confers immunore- 
activity not only to mAb NKI-beteb, but also to two other 
mAbs used to diagnose m alignant melanoma, HMB-50 
and HMB-45. In this report, we dem onstrate that 
gplOO-cl cDNA encodes glycoproteins of 100 kDa (gplOO) 
and 10 kDa (gplO) w hich are recognized by these mAbs 
in  hum an melanoma cells. The translation product de­
duced from the open reading frame present in  gplOO-cl 
cDNA is highly hom ologous to another m elanocyte-spe- 
cific protein, Pm ell7. Nucleotide sequence analysis of 
genom ic DNA indicates that the transcripts correspond­
ing to gplOO and P m ell7  cDNAs originate from a single  
gene via alternative splicing. In all normal and m alig­
nant m elanocytic cells analyzed, gplOO and P m ell7  
RNAs are sim ultaneously expressed.
Melanoma is a neoplasm th a t originates from melanocytes, 
pigment-producing cells in the skin. Melanoma is a relatively 
immunogenic tumor, as demonstrated by the presence of both 
cytotoxic T lymphocytes (CTL)1 (Knuth et aL , 1992) and anti­
bodies (Mattes et a t ,  1983) reacting with melanoma cells in 
patients. Characterization of the antigens recognized revealed 
tha t they include both tumor-specific antigens (van der Brug- 
gen et al., 1991) and the melanocyte differentiation antigens 
tyrosinase (Bricliard et al,, 1993) and gp75 (Vijayasaradhi et 
al.j 1990). Both these differentiation antigens are localized in a 
distinct cellular organelle, the melanosome, and are involved in 
the synthesis of the pigment melanin (Hearing and Tsukamoto,
1991). To understand the potential role of immunological 
events in the pathogenesis and clinical course of melanoma, it 
is important to identify more of these antigens. This will not 
only result in the identification of potential targets for immune 
responses against melanoma, it may also lead to the identifi­
cation of antigens involved in melanocyte differentiation and 
possibly transformation.
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Many monoclonal antibodies have been raised against mela­
noma cells. Clinical and pathological analyses using these 
mAbs have led to the description of different steps in the trans­
formation and progression of melanoma (reviewed by Ruiter et 
al, (1990)). Some of these mAbs define im portant markers in 
the initial diagnosis of melanoma, while others define mela­
noma progression antigens. Most of the antigens are expressed 
by both melanoma cells and melanocytes and are probably ex­
pressed during melanocyte differentiation. The melanocyte lin­
eage-specific antigens recognized by mAb NKI-beteb are among 
the best diagnostic m arkers for hum an melanoma (Vennegoor 
et al., 1988). NKI-beteb reacts with melanoma cells throughout 
tumor development and does not cross-react w ith other tumor 
cell types or normal cells, except for cells of the melanocytic 
lineage. The antigens recognized by NKI-beteb are glycopro­
teins of approximately 10 kDa (gplO) and 100 kDa (gplOO). 
U ltrastructural analysis of NKI-beteb binding sites indicates 
tha t the antigens are localized in premelanosomal vesicles 
(Vennegoor et al., 1988). Recently, we isolated a cDNA clone, 
gplOO-cl, which confers immunoreactivity to NKI-beteb after 
expression in gp 100-negative BLM melanoma cells (Adema et 
al.y 1993). Interestingly, two other mAbs used to diagnose ma­
lignant melanoma, HMB-50 (Vogel and Esclamado, 1988) and 
HMB-45 (Gown et al., 1986), also react with BLM cells trans­
fected with gplOO-cl cDNA (Adema etal., 1993), indicating that 
all three mAbs recognize proteins encoded by a single cDNA. 
Herein, we report the molecular characterization of gplOO-cl 
cDNA and the melanocyte lineage-specific protein it encodes 
and discuss oncological and cell-biological aspects of the gplOO 
antigen.
MATERIALS AND METHODS
Cells and Monoclonal Antibodies—The melanoma cell lines Mel-2a, 
M14, MEWO, and BLM (Adema et al., 1993) and the uveal melanoma 
cell line Mel 202 (Ksander et al. ,1991) have been described. Isolation of 
human melanocytes from breast or foreskin was performed by the 
method of Eisinger and Marko (1982) with modifications by (Smit et al., 
1993). NKI-beteb and HMB-50 have been described previously (Venne­
goor et aL, 1988; Vogel and Esclamado, 1988). HMB-45 was purchased 
from Enzo Biochem.
DNA Constructs, Transfections, and Immunofluorescence—gplOO-cl 
cDNA was cloned in both orientations (pSVLgplOO* and pSVLgplOO-) 
in the Sm al site of the eukaryotic expression vector pSVL (Pharmacia 
Biotech Inc.). pSVL contains the SV40 late promoter and polyadenyla- 
tion site, as well as the SV40 origin of replication, allowing a very 
high copy number during transient expression in COS-7 cells. For 
the construction of the 3' truncated gplOO transcription unit 
pSVLgpl00+(ABS), we deleted the sequence between the Bglll site in 
the 3' part of gplOO-cl cDNA and the SacI site in the vector. The 
resulting construct encodes a truncated gplOO protein in which the 
carboxyl-terminal 133 amino acids of gplOO are replaced by 4 amino 
acids (Arg-Ile-Gln-Thr) encoded by vector sequences. Transient expres­
sion of the constructs in COS-7 cells was performed by using 40 pg/ml 
Lipofectin reagent from Life Technologies, Inc. (Feigner et al., 1987) and 
7.5 pg of DNA. Transfected COS-7 cells were prepared for immunofluo-
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Pig* 1. E x p re ss io n  of gplOO-cl cDNA 
in  n o n -p ig m e n te d  COS-7 cells. COS-7 
cellg transfected with either gplOO-cl 
cDîsfÀ in  the coding (pSVLgpl00+; a, c, 
a n d  e) or non-coding (pSVLgplOO-; 6, d, 
a n d  f )  orientation, were analyzed for reac­
tiv ity  w ith  NKI-beteb (a and 6), HMB-45 
(c an d  d), or HMB-50 (e and f), respec­
tively. Indirect immunofluorescence (fluo­
resce in  isothiocyanate) was examined by 
confocal laser scanning microscopy. Mag­
nification, x 40.
b
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rescence as described previously (Adema et a l ,  1993) and examined 
u s in g  a  confocal laser scanning microscope at 488 nm (Bio-Rad MRC 
600).
Metabolic Labeling\ Immunoprécipitations, and  VS Protease 
M a p p in g —Immunoprécipitation experiments were performed on meta- 
bolically  labeled (L-[35S]methionine/cysteine; Amersham Corp.) cells as 
described by Vennegoor et al. (1988) using either NKI-beteb or HMB-50 
covalently  linked to protein A-Sepharose CL-4B beads (Pharmacia). In 
som e experiments, tunicamycin (75 pg/ml, Calbiochem) was added dur­
in g  th e  prelabeling period and remained present during the metabolic 
lab e lin g  reaction (12.5 min), Immunoprecipitates were analyzed under 
red u c in g  conditions by SDS-PAGE using 5-17.5% gradient gels. The 
re la tiv e  molecular weight of the proteins was determined using co- 
el ectrophoresed, prestained markers (Life Technologies, Inc,). Gels were 
tre a te d  w ith 1 m sodium salicylate (pH 5,4) prior to autoradiography 
(K odak XAR).
V8 protease mapping was performed using the procedure described 
b y  Cleveland et al. (1977). Briefly, gel slices containing the 100-kDa 
p ro te in s  were placed in the wells of a second SDS gel (10%) and overlaid 
w ith  Staphylococcus aureus V8 protease (2.5 pg/sample, Miles Labora­
tories). After electrophoresis, gels were treated as described above.
Molecular Cloning of Part of the gplOO!Pmell7 Gene—Part of the 
g p l0 0 /P m ell7  gene was amplified by PCR on hum an genomic DNA 
iso la ted  from peripheral blood lymphocytes using the following primers:
1497/1516 (5'-TATTGAAAGTGCCGAGATCC-3 ') and 1839/1857 (5'-TG~ 
CAAGGACCACAGCCATC-3'). The PCR products were subsequently
am plified  using a nested set of primers containing an additional EcoRl 
s ite  (underlined) ( 5 * -TATCTAGAATTCTGC ACC AGATACTGAAG-3 ' 
a n d  5 '-TATCTAGAATTCTGCAAGATGCCCACGATCAG-3 ' ) and cloned 
in to  th e  EcoRI site of pUC 18.
R N A  Isolation and Analysis—Total RNA was isolated using the gua­
n id ine  thiocyanate/cesium chloride procedure (Chirgwin et a l,  1979). 
cDNA w as prepared using the GeneAmp RNA PCR kit (Perkin-Elmer), 
an d  PCR analysis was performed for 35 cycles in the presence of 3 mM 
M gCl2 using primers 1497/1516 and 1839/1857 (see above) as described 
(Adem a and Baas, 1991). The reaction products were analyzed by 
S o u th e rn  blotting and hybridization to 32P-labeled oligonucleotide 
p robes as described previously (Adema and Baas, 1991). As probes, we 
u sed  either a gp 100-specific exon/exon junction oligonucleotide (5'-CT- 
TCTTGACCAGGCATGATA-3') or a Pmel 17-specific oligonucleotide (5'- 
TGTGAGAAGAATCCCAGGCA-3') that corresponds to 20 of the addi­
tional 21 nucleotides present in Pmell7 cDNA, In  every hybridization 
experim ent, a spot blot containing an oligonucleotide comprising the 
Pm el 17 exon/exon junction (5' -GCTTATCATGC CTGTGCCTGGAT- 
TCTTCTCACAGGT-3') was included as a control.
Nucleotide Sequence Analysis—gpl00-cl cDNA and genomic DNA 
clones were sequenced by the dideoxynucleotide sequencing method 
(Sanger et al., 1977) using T7 DNA polymerase (Pharmacia). The se­
quence of both strands was determined in each case. Since the genomic
DNA clones were obtained after PCR, the sequence of four independent 
clones was determined. Analysis of the DNA sequence was performed 
using the University of Winconsin Genetics Computing Group sequence 
analysis programs (Devereux et al. , 1984).
RESULTS
Expression o f gpl00-cl cDNA in Non-pigmented COS-7 Cells 
Results in Immunoreactivity with fnAbs NKI-beteb, HMB-50, 
and HMB-45—Expression of gpl00-cl cDNAin gp 100-negative 
BLM melanoma cells results in immunoreactivity with the 
melanocyte lineage-specific mAbs NKI-beteb, HMB-50, and 
HMB-45 (Adema et al., 1993). To determine whether expression 
of gpl00-cl cDNA in non-melanocytic cells also results in im­
munoreactivity with these mAbs, we performed transient ex­
pression experiments in COS-7 cells (monkey kidney fibro­
blasts) with constructs containing gpl00-cl cDNAin the coding 
or non-coding orientation. As shown in Fig. 1, only COS-7 cells 
transfected with the construct containing the cDNA in the cod­
ing orientation (COS-7/pSVLgplOO+) reacted with all three 
mAbs. These data demonstrate that immunoreactivity with 
NKI-beteb, HMB-50, and HMB-45 after expression of gpl00-cl 
cDNAis not restricted to melanocytic cells. In addition, these 
data show th a t the COS expression system can be used for 
further biochemical characterization of the proteins encoded by 
gpl00-cl cDNA.
Analysis o f the Proteins Encoded by gpl00-cl cDNA—To 
characterize the proteins encoded by gpl00-cl cDNA, COS-7/ 
pSVLgplQ0+ cells were metabolically labeled and subjected to 
immunoprécipitation with NKI-beteb or HMB-50. As shown in 
Fig. 2„ NKI-beteb (panel A )  and HMB-50 (panel B ) specifically 
detected proteins of approximately 100 kDa (95-110 kDa) in 
extracts of COS-7/pSVLgplOO+ cells. The molecular mass of 
these proteins is similar (see also below) to those detected in 
extracts of metabolically labeled ME WO cells (Fig. 2), which 
express the antigens endogenously (Vennegoor et a l,  1988). 
Consistent with previous reports (Vennegoor et at., 1988; Vogel 
and Esclamado, 1988), both mAbs also recognize a protein of 10 
kDa in extracts of MEWO cells (Fig. 2, lanes 6 and 7). A protein 
of the same size reacted w ith NKI-beteb in COS-7/pSVLgplOO+ 
cells (Fig. 2A, lane 4) and could be discerned with HMB-50 after 
prolonged exposure (not shown). No specific proteins were im- 
munoprecipitated by either of the mAbs from extracts prepared
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Fig. 2. P ro te in s  recogn ized  by NKI- 
be teb  (p a n e l  A) a n d  HMB-50 (p a n e l  
B) in  ex trac ts  from  gplOO-cl cDNA- 
tra n s fe c te d  COS-7 cells. MEWO cells 
(MEWO) and COS-7 cells transfected 
with either pSVLgplOO+ {COS+) or pSV- 
LgplOO- (COS-) were metabolically la­
beled and subjected to immunoprécipita­
tions using NKI-beteb (NKI-b), HMB-50 
(50), or normal mouse serum (NMS) as 
indicated above each lane, Immunopre- 
cipitated proteins were analyzed under 
reducing conditions by SDS-PAGE (linear 
gradient of 5-17% acrylamide) and visu­
alized by autoradiography. The 10-kDa 
protein is indicated by an asterisk. The 
position and size (kDa) of prestained mo­
lecular weight markers are indicated.
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from COS-7 cells transfected with the construct containing the 
cDNAin the non-coding orientation (Fig. 2). Comparison of the 
culture medium of metabolically labeled COS-7/pSVLgp 1004- 
cells and MEWO cells revealed tha t both mAbs also recognized 
proteins of about 100 kDa (see also below) in the culture me­
dium of these cells (Fig. 3). No proteins of 10 kDa were immu- 
noprecipitated by the mAbs from the culture medium of COS- 
7/pSVLgpl00+ cells, as has been shown for melanoma cells.
To exclude the possibility tha t the proteins detected by the 
mAbs are derived from endogenous genes induced after tran s­
fection with gpl00-cl cDNA, we performed immunoprécipita­
tion experiments with COS-7 cells expressing a 3' truncated 
gplOO transcription un it (see “Materials and Methods”). As 
shown in Fig. 4, proteins of approximately 85 kDa were de­
tected by both mAbs in COS-7 cells expressing this construct, 
consistent with a deletion of 129 amino acids. This finding 
provides direct evidence th a t the 100-kDa protein recognized 
by NKI-beteb and HMB-50 in COS-7/pSVLgplOO+ cells is en­
coded by gpl00-cl cDNA.
The 100-kDa Protein Encoded by gpl00-cl cDNA Is Identical 
to gplOO—The proteins of about 100 kDa identified by NKI- 
beteb and HMB-50 in COS“7/pSVLgplOO+ cells versus MEWO 
cells had a slightly different mobility when analyzed by SDS- 
PAGE (Fig. 2). This difference could be due to altered glycosy- 
lation, an event frequently observed in the COS expression 
system. Analysis of the proteins immunoprecipitated from 
MEWO cells and COS-7/pSVLgplOO+ cells cultured in the pres­
ence of the glycosylation inhibitor tunicamycin demonstrated 
tha t in both cell types the size of the proteins of about 100 kDa 
was reduced to two protein bands of 90 and 85 kDa, confirming 
that the difference in mobility is due to altered glycosylation 
(not shown).
To provide further evidence th a t the proteins recognized by 
NKI-beteb in COS-7/pSVLgplOO+ cells and MEWO cells are 
identical, we performed a V8 pro tease mapping experiment. As 
shown in Fig. 5, the same protein fragments were obtained 
after V8 protease digestion of the major 100-kDa protein iso­
lated from COS-7/pSVLgplOO+ cells or MEWO cells. We con-
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Fig. 3. Proteins recognized by NKI-beteb and HMB-50 in cul­
ture medium from gpl00-cl cDNA-transfected COS-7 cells. Cul­
ture medium from metabolically labeled MEWO cells (MEWO) or 
COS-7 cells transfected with pSVLgpl00+ (COS+) or pSVLgplOO- 
(COS-) was subjected to immunoprécipitations using NKI-beteb (NKI- 
6), HMB-50 (50) ,  or normal mouse serum (NMS) as indicated above 
each lane. Analysis by SDS-PAGE and molecular weight markers were 
as described in Fig. 2.
elude from these data th a t gplOO-cl cDNA encodes the mela­
nocyte lineage-specific glycoprotein gplOO recognized by NKI- 
beteb and HMB-50 in melanoma cells.
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Fig. 4. P roteins recognized by NKI-beteb and HMB-50 in COS-7 
c e lls  expressing a truncated gplOO transcription unit. Extracts 
from metabolically labeled COS-7 cells transfected with pSVLgplOO* 
(gplO O ) or the 3' truncated construct pSVLgpl00+(ABS) (gplOOà), see 
‘‘M ateria ls  and Methods”) were subjected to immunoprécipitations us­
in g  NKI-beteb (NKI-h), HMB-50 (50), or normal mouse serum (NMS) 
as indicated above each lane. Analysis by SDS-PAGE and molecular 
w e ig h t m arkers were as described in Fig. 2.
gplOO Is a Type I  Transmembrane Protein Highly Homolo­
g o u s  to P m e ll?—The nucleotide sequence of gplOO-cl cDNA 
w as determ ined. It contains 2115 base pairs and terminates 
w ith  a poly(A) tract of 15 nucleotides, preceded by the consen­
su s polyadenylation sequence AATAAA (Proudfoot and Brown­
lee > 1976). An open reading frame extending from position 22 
th ro u g h  2007 is present in gplOO-cl cDNA. This open reading 
fram e s ta rts  with an ATG codon within the appropriate se­
quence context for translation initiation (Kozak, 1987) and pre­
d ic ts  a  protein of 661 amino acids (Fig, 6). The amino-terminal 
20  am ino acids fit all criteria for signal sequences, including a 
p o ten tia l cleavage site after Ala at position -1  (von Heyne, 
1986), implying that mature gplOO contains 641 amino acids 
(approxim ately 70 kDa). Based on hydrophobicity plot analysis 
(K yte and  Doolittle, 1982), a single transm em brane domain 
bordered  by charged residues is present in the  carboxyl-termi­
n a l p a r t  (positions 571-591) of gplOO. The predicted cytoplas­
m ic dom ain is 45 amino acids long. Five putative AMinked 
glycosylation sites are present, consistent w ith gplOO being a 
glycoprotein. Furthermore, a histidine-rich domain (position 
162-293), a threonine-rich domain (position 289-407) with re­
p e titiv e  amino acid sequences, and a cysteine-rich domain (po­
sition  455—546) are present.
A  da ta  base search (Pearson and Lipman, 1988; Altschul et 
aLy 1990) revealed that gplOO is almost identical to Pm ell7, 
an o th er melanocyte-specific protein (Kwon et al.} 1991). The 
am ino acid differences between gplOO and Pmel 17 consist of 
substitu tions a t position 254 (T — > C/Pro —* Leu) and 577 (C — » 
G/Arg -9- Pro) and a stretch of 7 amino acids absent in gplOO at 
position 567 (see also Table II). A single nucleotide difference a t 
position 762 (C - >  T) does not result in  an amino acid substi-
1 2
F ig . 5, V8 protease m apping of the major 100-kDa protein de­
tected b y  NKI-beteb in COS-7/pSVLgplOO+ cells and MEWO 
cells. Gel slices containing the major 100-kDa protein detected by NKI- 
beteb in MEWO cells (lane 2) and COS-7/pSVLgplOO+ cells (lane 1) 
were subjected to V8 pro tease digestion as described by Cleveland et ah 
(1977). The resulting protein fragments were analyzed by SDS-PAGE 
(10%). Molecular weight markers were as indicated in Fig. 2.
tution, gplOO is also 80% homologous to a putative protein 
deduced from a partial bovine cDNA clone (RPE-1) (Kim and 
Wistow, 1992) and 42% homologous to a chicken melanosomal 
matrix protein, MMP115 (Mochii et al. ,  1991).
gplOO and Pm ell7  Are Encoded by a Single Gene—The most 
striking difference between gplOO and Pmel 17 cDNAs is the 
in-frame deletion of 21 bp in  gplOO cDNA. Possibly, both cDNAs 
correspond to transcripts generated by alternative splicing of a 
single primary transcript. To test this hypothesis, we used PCR 
to analyze the genomic DNA corresponding to the part of the 
gplOO gene surrounding the putative alternative splice site. 
Comparison of the nucleotide sequence of this genomic DNA  
with the sequence of gplOO-cl cDNA revealed the presence of 
an intron (102 bp) ju s t a t the position of the 21-bp insertion in 
Pmell7 cDNA (Table I). The exon/intron boundaries nicely fit 
the consensus 5' donor and 3; acceptor splice site sequences 
(Padgett et a l ,  1986), In the genomic DNA, the sequence com­
prising the additional 21 bp in Pmell7 cDNAis located directly 
upstream of this 3 r cleavage site and is preceded by an alter­
native 3' acceptor splice site (Table I). Whereas the gplOO- 
specific 3' acceptor splice site fits the consensus sequence, the 
Pmell7-specific 3' acceptor splice site appears to be subopti- 
mal, in th a t it lacks a pyrimidine-rich region (Table I). Subop-
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1 cg cg g aa tccg g aag aacacaa tg g a tc tg g t g e t a a a a a g a tg c c t tc t  t e a t  t tg g c tg tg a ta g g tg c t t tg c tg g c tg tg g g g g c t
M D L V L K R C L L J H __L A V __I__G A L L — V G A
+1
91 acaaaag taeccag aaaccag g ac tg g c ttg g tg tc tcaag g caac tcag aaccaaag cc tg g aacag g cag c tg ta tccag ag tg g aca
24 t k v p r n q d w l g v s r q l r t k a w n r q l y p e w t
181 g a a g c c c a g a g a c t tg a c tg c tg g a g a g g tg g tc a a g tg tc c c tc a a g g tc a g ta a tg a tg g g c c ta c a c tg a t tg g tg c a a a tg c c tc c  
54 E A Q R L D C W R G G Q V S L K V S N D G P T L I G A N A S
*
271 t tc tc ta t tg c c t tg a a c t tc c c tg g a a g c c a a a a g g ta t tg c c a g a tg g g c a g g t ta tc tg g g tc a a c a a ta c c a tc a tc a a tg g g a g c  
84 F S I A L N F P G S Q K V L P D G Q V I W V N N T I I N G S* *
361 c a g g tg tg g g g a g g a c a g c c a g tg ta tc c c c a g g a a a c tg a c g a tg c c tg c a tc t tc c c tg a tg g tg g a c c t tg c c c a te tg g c tc t tg g  
114 Q V W G G Q P V Y P Q E T D D A C  I F P D G G P C P S G  S W
451 tc tc a g a a g a g a a g c t t tg t t ta tg tc tg g a a g a c c tg g g g c c a a ta c tg g c a a g t tc ta g g g g g c c c a g tg tc tg g g c tg a g c a t tg g g
144 S Q K R S F V Y V W K T W G Q Y W Q V L G G P V S G L S  I G
541 a c a g g c a g g g c a a tg c tg g g c a c a c a c a c c a tg g a a g tg a c tg tc ta c c a tc g c c g g g g a tc c c g g a g c ta tg tg c c tc t tg c tc a t tc c  
174 T G R A M L G T H T M E V T V Y H R R G S R S Y V P L A H S
631 a g c tc a g c c t tc a c c a t ta c tg a c c a g g tg c c t t tc tc c g tg a g c g tg tc c c a g t tg c g g g c c t tg g a tg g a g g g a a c a a g c a c t tc c tg
204 S S A F T I T D Q V P F S V S V S Q L R A L D G G N K H F L
721 a g a a a tc a g c c tc tg a c c t t tg c c c tc c a g c tc c a tg a c c c c a g tg g c ta tc tg g c tg a a g c tg a c c tc tc c ta c a c c tg g g a c t t tg g a  
234 R N Q P L T F A L Q L H D P S G Y L A E A D L S Y T V i D F G
811 g a c a g ta g tg g a a c c c tg a tc tc te g g g c a c t tg tg g tc a c tc a ta c t ta c e tg g a g c e tg g c c c a g tc a c tg c c c a g g tg g tc c tg c a g  
264 D S  S G T L I  S R A L V V T H T Y L E P G  P V T A Q V V L Q
901 g c tg c c a t tc c tc tc a c c tc c tg tg g c tc c tc c c c a g ttc c a g g c a c c a c a g a tg g g c a c a g g e c a a c tg c a g a g g c c c c ta a c a c c a c a  
294 A A I P L T S C G S  S P V P G T T D G H R P T A E A P N T T*
991 g c tg g c c a a g tg c c ta c ta c a g a a g ttg tg g g ta c ta c a c c tg g tc a g g c g c c a a c tg c a g a g c c c tc tg g a a c c a e a tc tg tg c a g g tg  
324 A G Q V P T T E V V G T T P G Q A P T A E P S G T T S V Q V
1081 c ca a c cac tg a ag tca taag cac tg cacc tg tg cag a tg ccaac tg cag ag ag cacag g ta tg acacc tg a g aag g tg ccag tt tc ag ag  
354 P T T E V I  S T A P V Q M P T A E S T G  M T P E K V P V  S E
1171 g tc a tg g g ta c c a c a c tg g c a g a g a tg tc a a c tc c a g a g g c ta c a g g ta tg a c a c c tg c a g a g g ta tc a a t tg tg g tg c t t tc tg g a a c c  
384 V M G T T L A E M S T P E A T G M T  P A E V S  I V V L S  G T
1261 acag c tg cacag g taacaac tacag ag tg g g tg g ag accacag c tag ag ag c tacc ta tccc tg ag cc tg aag g tccag a tg ccag c tca  
414 T A A Q V T T T E W V E T T A R E L P I P E P E G P D A S  S
1351 a tc a tg tc ta c g g a a a g ta t ta c a g g t tc c c tg g g c c c c c tg c tg g a tg g ta c a g c c a c c t ta a g g c tg g tg a a g a g a c a a g tc c c c c tg  
444 I M S T E S  I T G S L G P L L D G T A T L R L V K R Q V P L
1441 g a t tg tg t tc tg ta tc g a ta tg g t tc c t t t t c c g tc a c c c tg g a c a t tg tc c a g g g ta t tg a a a g tg c c g a g a tc c tg c a g g c tg tg c c g  
474 D C V L Y R Y G S F S V T L D I V Q G I E S A E I L Q A V P
1531 tccg g tg ag g g g g a tgca ttfcgagc tgac tg tg tcc tgccaaggcgggc tgcccaaggaagcc tgca tggaga tc tca tcgccaggg tgc  
504 S G E G D A F E L T V S C Q G G L P K E A C M E I S S P G C
1621 cag ccccc tg cccag cg g c tg tg ccag cc tg tg c tacccag cccag cc tg ccag c tg g ttc tg caccag a tac tg aag g g tg g c tcg g g g  
534 Q P P A Q R L C Q P V L P S P A C Q L V L H Q I L K G G S G
1711 a c a ta c tg c c tc a a tg tg tc tc tg g c tg a ta c c a a c a g c c tg g c a g tg g tc a g c a c c c a g c t ta tc a tg o c tg g tc a a g a a g c a g g c c t t  
564 T Y C L N V S L A D T N S L A V V S T Q L I M P G Q E  A G L
*
1801 g g g c a g g t tc c g c tg a tc g tg g g c a tc t tg c tg g tg t tg a tg g c tg tg g tc c t tg c a tc tc tg a ta ta ta g g c g c a g a c t ta tg a a g c a a  
594 G O V P L I  V G  I L L V L M A V V L A S  L I Y R R R L M K Q
1891 g a c t tc tc c g ta c c c c a g t tg c c a c a ta g c a g c a g tc a c tg g c tg c g tc ta c c c c g c a tc t to tg c tc t tg tc c c a t tg g tg a g a a ta g c  
624 D F S V P Q L P H S S S H W L R L P R I F C S C P I G E N S
1981 c c c c tc c tc a g tg g g c a g c a g g tc tg a g ta c tc tc a ta tg a tg c tg tg a t t t tc c tg g a g t tg a c a g a a a c a c c ta ta t t tc c c c c a g tc  
654 P L L S G Q Q V
2071 t tc c c tg g g a g a c ta c ta t ta a c tg a a a ta a a ta c tc a g a g c c tg a a a a a a a a a a a a a a a
F i g , 6 .  Nucleotide sequence of gplOO-cl cDNA and the deduced amino acid sequence. The poly(A) addition site is indicated in italics. 
The deduced amino acid sequence contains a putative signal peptide (underlined). The first amino acid of mature gplOO is designated +1. Putative 
TV-linked glycosylation sites are indicated by an asterisk > whereas the transmembrane region is underlined.
T a ble  I
Genomic organization o f part of the human gplOO [Pmell7 gene
A and A' represent the introns that are removed in transcripts corresponding to gplOO-cl cDNA and Pmell7 cDNA, respectively Exon sequences 
are indicated in uppercase and intron sequences as lowercase letters. The best fit to the branch point sequence (Ruskin et ah, 1984) is underlined.
Intron Sizei i
> 
i>
i i 1 !
nt
102
81
CATGCCTGgtaggtcc
CATGCCTGgtaggtcc
. . . . agacactgagtgaagcagtgcctgggattcttctcacagGTCAAAG
timal RNA processing sites are present in many alternatively 
processed messenger RNA precursors and have been impli­
cated to function in regulation of alternative RNA processing 
(reviewed by Green (1991)). These data prove th a t gplOO and 
Pm ell7 transcripts are generated by alternative splicing of a 
single primary transcript and thus originate from a single gene.
Expression of gplOO and Pm ell7 RN As in Cells of the Mela- 
nocytic Lineage—The finding th a t gplOO and Pm ell7 RNAs 
arise by alternative splicing of a single primary transcript 
raises the question of whether this occurs in a regulated man­
ner. Previously, we showed that an RNA species of 2.5 kilobases 
is the major RNA product detected by gplOO-cl cDNA on North-
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Fig. 7. Expression of gplOO and Pm ell7 RNA in  cells of the 
melanocytie lineage. Reverse transcriptase/PCR was performed on 
ENA isolated from MEWO (lanes 2), BLM (lanes 3), M14 (lanes 4), 
Mel2a (lanes 5) cutaneous melanoma cells, the uveal melanoma cells 
Mel 202 (¿ernes 0), neonatal melanocytes (lanes 6 and 7), and adult 
(lanes 8) melanocytes, As a control, PCR was performed on gplOO-cl 
cDNAQanes 2). The reaction products were analyzed by Southern blot­
ting and hybridization to either a gp 10O-specific (left panel) or a 
Pmell7-specifxc (right panel) oligonucleotide probe. As a control, both 
probes were hybridized to a spot blot containing different amounts (100, 
10, and  1 ng) of the Pmell7-specific exon/exon junction. The position of 
the DNAspecies corresponding to Pmell7 and gplOO spliced products as 
well as unspliced material and/or contaminating genomic DNA (*) are 
indicated. Note th a t the gp 100-specific exon/exon junction probe does 
not react with DNA species corresponding to unspliced material/ 
genomic DNA.
ern blots containing RNA isolated from melanocytic cells. Es­
sentially th e  same results were obtained by Kwon et al, (1987) 
using Pm el 17-1 cDNA as a probe. However, neither of the 
probes discrim inate between gplOO and Pm ell7 RNAs. There­
fore, we performed a reverse transcriptase/polymerase chain 
reaction assay followed by Southern blotting and hybridization 
to either a  gpl00-specific exon/exon junction or a Pmell7-spe- 
cific oligonucleotide probe (see “Materials and Methods”). As 
shown in Fig. 7, gplOO and Pmell7 spliced products were both 
detected in  three out of four cutaneous melanoma cells (lanes 2,
4, and 5) and in uveal melanoma cells (lanes 9 \  as well as in 
neonatal (lanes 6 and 7) and adult melanocytes (lanes 8). Both 
spliced products were also present in three different primary 
melanomas (not shown). No products were detected with either 
probe in g p l 00-negative BLM melanoma cells (lanes 3 ). These 
results dem onstrate that in all melanocytic cells examined,t 
gplOO and  Pm ell7  RNAs are expressed simultaneously.
DISCUSSION
Herein, we demonstrate th a t gplOO-cl cDNA encodes the 
melanocyte line age-specific antigens recognized by mAbs NKI- 
beteb, HMB-50, and HMB-45, which are valuable diagnostic 
m arkers for melanoma. Expression of gplOO-cl cDNAin COS-7 
cells dem onstrates that NKI-beteb and HMB-50 recognize the 
same proteins of 100 and 10 kDa. Comparison of the 100-kDa 
protein in  these cells and MEWO melanoma cells by V8 prote­
ase digestion demonstrates that they have the same protein 
backbone. The relationship between the 100- and 10-kDa pro­
teins is not clear at present. The 10-kDa protein may be derived 
from the 100-kDa protein either by specific proteolytic process­
ing or by degradation. Two findings lend support to the latter 
explanation, (a) The amount of 10-kDa proteins relative to the 
am ount of 100-kDa proteins varies considerably between ex­
perim ents, and (b) the 10-kDa protein can only be detected 
after a  labeling period of 2 h  while the 100-kDa protein is 
already present in the culture medium after 1 h  (Esclamado et 
al., 1986; results not shown).
In addition to NKI-beteb and HMB-50, HMB-45 also reacts 
w ith g p l00-transfected COS-7 cells. HMB-45 has been reported 
to immunoprecipitate proteins of 10 kDa from extracts and of 
100 kD a from culture medium of melanoma cells, both of which
comigrate with those detected by HMB-50 and NKI-beteb 
(Esclamado et al., 1986; Vennegoor et al., 1988). In addition, an 
additive enzyme immunoassay revealed an additivity index of 
91% for the mixture of HMB-45 and NKI-beteb (Vennegoor et 
a l , 1988). For our study, HMB-45 could not be obtained in 
sufficient amounts to directly analyze the proteins it detects in 
COS-7/pSVLgplQO+ cells. However, the combined data of the 
authors mentioned above and those described herein indicate 
that the antigens recognized by HMB-45 are also encoded by 
gplOO-cl cDNA.
Proteins Homologous to gplOO—A data base search revealed 
that gplOO is almost identical with the melanocyte-specific pro­
tein Pmell7. The cDNA encoding Pmell7 was isolated from a A. 
g il l  melanocyte cDNA library (Kwon et a l ,  1987; 1991). The 
most striking difference between gpl00~cl and Pmell7 cDNA 
consists of an in-frame deletion of 21 bp in gplOO-cl cDNA. 
Nucleotide sequence analysis of part of the gene encoding 
gplOO demonstrates th a t both cDNAs correspond to transcripts 
originating from a single gene via alternative splicing. A single 
5' donor splice site is used in combination with two different, 
partially overlapping, 3' acceptor splice sites. No regulated ex­
pression of gplOO and Pm ell7 mRNAs in ceils of the melano­
cytic lineage has been observed; cells either expressed neither 
of the mHNAs or both. These data are consistent with previous 
results obtained by Kwon et al. (1987,1991), indicating th a t the 
gene encoding Pmell7, and hence the gplOO gene, is a single­
copy gene th a t maps to hum an chromosome 12 (region 12 pter- 
q21). Three other nucleotide differences have been detected 
between gplOO and Pm ell?, two of which give rise to an amino 
acid substitution. They may represent allelic variations or poly­
morphisms, but we cannot exclude the possibility that they 
result from mutations.
In addition to Pm ell7, gplOO was found to be 80% homolo­
gous to the putative protein (RPE1) product encoded by a par­
tial bovine cDNA isolated from retinal pigment epithelium 
(RPE) (Kim and Wistow, 1992). Bovine EPE has been shown to 
react with HMB-50 (Kim and Wistow, 1992) and human RPE 
with HMB-45 (Kapur et al., 1992). Since the RPE1 protein is 
80% homologous to gplOO and lacks the 7 amino acids present 
in Pm ell7 (Table II), it  may well represent the bovine homo- 
logue of gplOO.
Another data base entry showing significant homology (42%) 
to gplOO is the  melanosomal matrix glycoprotein MMP115 iso­
lated from chicken RPE (Mochii et a l 1991). MMP115 local­
izes, as gplOO, in melanosomal vesicles. No function has been 
reported for MMP115. The amino-terminal sequence (670 
amino acids) of MMP115 is 46% homologous to the correspond­
ing p art in gplOO. The carboxyl-terminal part of MMP115 (84 
amino acids) is only 13% homologous to gplOO and does not 
contain a transm em brane domain. Strikingly, the homology 
between gplOO and MMP115 decreases just a t the site of the
7-amino acid insertion in Pm ell7 (Table II). Perhaps MMP115 
represents a soluble form of the chicken homologue of gplOO 
still to be discovered in man.
A data base search with the gplOO amino acid sequence or 
parts of this sequence did not reveal the presence of any known 
functional domain. The spacing of the cysteines in the cysteine - 
rich region th a t determines its tertiary fold is highly conserved 
between gplOO/Pmell7, RPE1, and MMP115 (Table II) but is 
distinct from the ones found in other protein families, e.g. the 
integrin (Kishimoto et a l ,  1989) or nerve growth factor receptor 
families (Mallett et al., 1991). Therefore, the cysteine-rich do­
main present in the Pmell7/gpl00 family may represent a 
novel structural or functional (interaction with other proteins) 
domain.
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T a b l e  II
Alignment of the carboxyl-terminal part of members o f the gplOO/Pmel 17 family
Identical amino acids (—) and gaps (*) are indicated. Conserved cysteine residues (#) are indicated as well.
GplOO PLDCVLYRYGSFSVTLDIVQGIESAEILQAVPS * * *GEGDAFELTVSCQGGLPKEA
Pmel 17
RPE1
MMP115 -TG--------------T— TE-N--------------V A -V -V — A A PE -S-N SV --------T -E -S — E-V
#  #  7^  #  7^
GplOO CMEISSFGCQPPAQRLCQPVLPSPACQLVLHQILKGGSGTYCLNVSLADTNSLAW
Pmel 17
RPEl — D--------------L------------------ P---------------------- V--------------------------------- A--------M-
MMpllS -TWADAE -RT AQMQT - S  A -A -A - G----------R-DFNQ*— L---------------- NG-G------A
GplOO STQLIMP*******GQEAGLGQVPLIVGILLVLMAVVLASLIYRRRLMKQ**DFSV
Pmel 17 --------------VPGILLT------------------ R------------------------------------------------------* * --------
RPEl ------- V— * * * * * * * ------------R -A — F --------------T -L L ---------------------------GSEVPL
MMP115 — HVAVGSIPSRQWHHAHRGAALGTAH-RCSGHRCLH-PPCEVQPAAAHSPHGPPA
GplOO PQLPHSSSHWLRLPRI*FCSCPIGENSPLLSGQQV
Pmel 17
RPEl --------- GRTQ---------- WV*-R------------SK----------------
MMP115 ----- AAPRCYPAFAAAPG-WGGSQWRKQ-PARANA-
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Melanocyte-specific Antigen gplOO: Cell-biological and Onco­
logical Significance—The synthesis of melanin in melanocytes 
is a multistep process regulated at different levels (reviewed by 
Hearing and Tsukamoto (1991)). Tÿrosinase (EC 1.14.10.1) is 
the key enzyme in this pathway and catalyzes the initial steps 
in the cascade of reactions leading to the production of melanin 
from the amino acid tyrosine. Two other members of the tyro­
sinase family are TRP-1 or gp75 (Shibahara et a l.y 1986; 
Vijayasaradhi et a l ,  1990) and TRP-2 (Jackson et al.t
1992), the latter of which contains 3,4-dihydroxy phenyl al a- 
nine(DOPA)chrome tautomerase (EC 5.3.2.3) activity (Tsuka­
moto et al.y 1992). The combined data on gplOO and Pm ell7 
imply th a t they are also related to this process; 1) both proteins 
are only expressed in pigmented cells (Kwon et a l 1987; Ven­
negoor et a l., 1988), 2) gplOO is present in melanosomal vesicles 
(Vennegoor et aLy 1988), and 3) an increase in the amount of 
transcripts derived from the gplOO/Pmell7 gene correlates 
with increasing levels of melanization (Kwon et aL, 1987). P re­
liminary data indicate th a t Pmel 17 also reacts with the anti- 
gplOO mAbs and is localized in melanosomes. Cumulatively, 
these data support a role of both gplOO and Pm el 17 in mela­
nization, either as enzymes regulating the quality or quantity 
of melanin synthesis or as structural components of the mela- 
nosome. The possibility that these proteins play a role in m a­
lignant transformation is not likely, but it cannot be excluded.
Melanoma is a relatively immunogenic tumor, demonstrated 
by the presence of both CTL (reviewed by Knuth et aLy 1992) 
and antibodies (Mattes et a l 3 1983) against melanoma cells in 
patients. The recent finding that some CTL clones react not 
only with melanoma cells but also with normal melanocytes 
suggests th a t tissue-related antigens can also be recognized 
(Anichini et al,, 1993). Moreover, Brichard et al. (1993) showed 
that a peptide derived from tyrosinase is recognized by a CTL 
clone. Recently, we have identified g p l00-specific tumor-infil­
trating lymphocytes in a melanoma patient (Bakker et al., 
1994). These data demonstrate that besides its value as a tu ­
mor marker, gplOO may also serve as a target for specific im­
munotherapy against melanoma, provided th a t no unaccept­
able side effects are observed against normal tissues harboring 
pigmented cells.
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